TORONTO, March 11, 2021 /PRNewswire/ -- Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has … A copy of the early warning report will be available on AION's issuer profile on SEDAR at www.sedar.com. Dr. De La Haye established the Medicinal Cannabis Unit in the Ministry of Health and Wellness in July 2017, supervising the registration of over 80 medicinal cannabis products in Jamaica. 3/11/2021 Aion Therapeutic, Inc. Thompson, Ph.D. as its new president.Dr. The centre will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). For further information, please contact: Plant-Based Investment Corp. A copy of the early warning report will be available on AION's issuer profile on SEDAR at www.sedar.com. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer 9/10/2020, "Using Artificial Intelligence to Unravel Ancient Healing Secrets", International Center for Psychedelic Psychiatry ➣. 2. to create disease specific patentable medical cannabis/mushroom formulation treatments to create Personalized Medicine. Early warning report - AION THERAPEUTIC INC. (formerly, Osoyoos Cannabis Inc.) Filed on: 02-22-2021. Biochemistry With Proprietary Artificial Intelligence Techniques. Compositions and Methods for Treatment of Psychoses and Psychotic Disorders The agreement reduces the Company's liabilities by $750,000 and improves the Company's financial position with respect to both, Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company"), a cannabinoid-focused processing and extraction company, is pleased to announce that, further to its press release of September 4, 2019, it has been advised by the Canadian Securities Exchange that trading in its common, Toronto, Ontario--(Newsfile Corp. - September 4, 2019) -  Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company) wishes to announce that its letter of intent with Anahit International Corp. ("Anahit") as previously announced on May 16, 2019 (the "LOI") has been terminated. Aion Therapeutic Processes and Analyzes Plant & Mushroom Genetics, Phenotypes and Press Releases by Aion Therapeutic Inc. ... TORONTO, March 11, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Aion Therapeutic utilizes artificial intelligence techniques to analyze patient specific genomic data to properly triage patients into the correct therapeutic formulations specifically designed for an individual patient thereby bringing medical cannabis and medicinal mushrooms treatments into the realm of true personalized medicine. Aion Therapeutic Inc ... SEDI Insider filings House positions SEDAR Documents Community Wiki Website. Aion Therapeutic has demonstrated in clinical laboratory research studies that medical cannabis and medicinal mushrooms also work together in healing and Aion Therapeutic is now in the process of bring these findings into clinical trials and starting commercial production of pharmaceuticals, nutraceuticals and cosmeceuticals combining these two special gifts of nature.